Other Briefings
China Issues New Fair Competition Review Regulations in Effort to Improve the Business Environment
The new rules prohibit local governments from including content that could favor or discriminate against certain companies when drafting legislation and policy measures.
China Releases ESG Reporting Standards for Businesses
China has released new ESG Reporting Standards, aiming for a mandatory, ISSB-aligned system by 2030, with key standards introduced by 2027.
New Data Security Risk Assessment Rules for Industry and Information Technology Sectors
New trial rules clarify data security risk assessments requirements for companies processing core and important data in the industrial and IT fields.
Complying with New Registered Capital Rules under China’s Revised Company Law
Companies established before the new company law comes into effect will have three years to adapt to new rules on registered capital in China.
China’s New Company Law: Considerations for Foreign Stakeholders and FIEs (update)
The New Company Law brings substantial changes with implications for new and existing foreign invested enterprises and stakeholders in China. Foreign investors must assess if adjustments to existing structures or new business negotiations are necessary.
China’s Revised Company Law in Effect from July 1, 2024: Key Details Here
The revised Company Law includes major changes to company capital rules, corporate governance structures, shareholder rights, and liquidation procedures.
China’s Enhanced Beneficiary Owner Filing System: Key Points of New Measures
China’s new beneficiary owner filing measures require business entities, except individually owned businesses, to submit their beneficiary owner information starting November 1, 2024, with a one-year grace period available for entities registered before that date.
Navigating China’s Evolving Approach to Human Genetic Resources: Insights on Regulatory Changes
China has transferred the management of human genetic resources to the National Health Commission, aiming to streamline regulations and foster biotech innovation by balancing oversight and reducing bureaucratic burdens. This shift is expected to enhance international collaboration, attract foreign investment, and expedite drug development in China.
